- Conditions
- Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
- Interventions
- ANS03
- Drug
- Lead sponsor
- Avistone Biotechnology Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 18,748
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Drug
- Lead sponsor
- Cerenome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 4
- States / cities
- Manhasset, New York • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- KarXT, Midazolam, Fexofenadine, Digoxin
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery
- Biological · Other · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Ewing Sarcoma
- Interventions
- Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
- Drug · Diagnostic Test · Other
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 6 Years to 99 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Healthy
- Interventions
- MBX 2109 (Part A), MBX 2109 (Part B), Placebo
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Solid Tumours
- Interventions
- ODM-212
- Drug
- Lead sponsor
- Orion Corporation, Orion Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orange, California • St Louis, Missouri + 5 more
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae
- Interventions
- GSK1349572, Efavirenz
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Healthy Volunteers
- Interventions
- RO7890597, Placebo, Rabeprazole, Itraconazole
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Pharmacokinetics
- Interventions
- VNRX-7145, Ceftibuten
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Parkinson's Disease
- Interventions
- Surgical infusion of AAV-GAD into the subthalamic nucleus
- Genetic
- Lead sponsor
- Neurologix, Inc.
- Industry
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Interventions
- Evofosfamide, Zalifrelimab, Balstilimab
- Drug
- Lead sponsor
- ImmunoGenesis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Interventions
- radiation therapy treatment planning/simulation, intensity-modulated radiation therapy, image-guided radiation therapy, magnetic resonance imaging, computed tomography
- Procedure
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Transplant
- Interventions
- IVIG and Rituximab
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Peripheral Neuropathy, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Interventions
- Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
- Other · Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more
- Conditions
- Imaging of Solid Gastrointestinal Tumors
- Interventions
- [68Ga]MLN6907
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study, stereotactic radiosurgery
- Drug · Other · Radiation
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Von Willebrand's Disease (VWD)
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine
- Other · Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Dengue
- Interventions
- D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
- Interventions
- RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more
- Conditions
- Healthy
- Interventions
- PRA023, Placebo
- Drug · Other
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska